PharmaFluidics raises 7.3 million euro to expand commercialization of novel micro-chip device for biomarker, diagnostics and drug development applications

PharmaFluidics NV, a game-changing innovator in the field of analytical chromatography, announced today that it has raised 7.3 million euro. The company will focus on intensifying international growth, supported by initial, promising sales.

Micro-Chip chromatography company PharmaFluidics closed a financing round of 7.3 million euro from investors including holding company FPIM-SFPI, and family offices Heran (Annie Vereecken) and RMM (Rudi Mariën). The existing investors PMV, Qbic, Theodorus, Innovation Fund and Volksvermogen reaffirm their confidence in the company and also participated in this financing round.

The VUB spin-off is a disruptive player in the field of micro-Chip Chromatography. Their unique technology – the µPACᵀᴹ column series – offers unprecedented robustness and reproducibility as well as state-of-the-art sensitivity and resolution performance. The first clients – academic labs in bio-analysis, bio-pharmaceuticals and diagnostics companies – have confirmed these outstanding characteristics of the µPACᵀᴹ technology.

The new funds will be used to further develop the Pillar Array technology platform, to expand the µPACᵀᴹ product range, and to scale up production and global sales. “This funding will significantly boost our capacity to support our growth,” said PharmaFluidics’ Managing Director Johan Devenyns.